Evidence-Based Nutraceuticals Derived from Antrodia cinnamomea
Author(s)
Xu, Chunyuhang; Xie, Qingtong; Kuo, Chien-Liang; Yang, Xin; Huang, Dejian
Downloadfoods-14-01212-v3.pdf (2.766Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Antrodia cinnamomea (A. cinnamomea), a medicinal and edible mushroom endemic to Taiwan, has been traditionally valued as a health tonic. Recent studies have highlighted the diverse specialized metabolites and bioactive potential of this substance, primarily attributed to key secondary metabolites such as benzenoids, maleic and succinic acids, ubiquinone, triterpenoids, and the primary metabolite polysaccharides. These compounds exhibit a broad spectrum of pharmacological properties, including those related to antibacterial, antitumor, anti-inflammation, hepatoprotection, hypoglycaemia, and antioxidant activities, and immunomodulation and gut microbiota regulation. These findings highlight the therapeutic potential of A. cinnamomea and its potential applications in health supplements and functional foods. This review evaluated recent advancements in the cultivation, extraction, and characterization of bioactive compounds from A. cinnamomea, with a particular focus on submerged and solid-state fermentation methods. We hope to provide a comprehensive framework for promoting the efficient and scientific evidence based utilization of A. cinnamomea in novel therapeutic strategies and health-related innovations.
Date issued
2025-03-30Department
Koch Institute for Integrative Cancer Research at MITJournal
Foods
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Xu, C.; Xie, Q.; Kuo, C.-L.; Yang, X.; Huang, D. Evidence-Based Nutraceuticals Derived from Antrodia cinnamomea. Foods 2025, 14, 1212.
Version: Final published version